title: Anti-tuberculosis programs in Thailand: a cost analysis.
abstract: The standard regimen, a combination of isoniazid and thiacetazone, which has been used for treatment of tuberculosis (TB) in Thailand for the past 20 years is inexpensive, but possesses a high degree of toxicity and requires 18-24 months of continuous treatment, resulting in poor compliance and a low success rate of treatment. The more efficacious short-course chemotherapy introduced into the National Tuberculosis Program in 1985 is limited by the high costs of drugs. However, the cost of providing care is not limited only to drug costs but also includes other services costs. The present study was undertaken to compare the total provider costs of 3 short-course regimens with that of the standard program in the treatment of newly diagnosed pulmonary TB. Data were collected at 4 zonal TB centers through out Thailand in 1987-1988. Analysis showed that the 3 short-course regimens had lower costs than the standard regimen from the provider perspective. Among these 3 regimens that of isoniazid, rifampicin and pyrazinamide for 2 months, followed by isoniazid and rifampicin twice a week for 4 months had the lowest costs (Baht 1,499). Despite the lowest drug cost (B 431) of the standard regimen, the total provider costs were the highest (B 2,541) due to the highest routine service cost of B 2,066. Thus to determine the cost of a disease requires consideration of both drug costs and also other cost components.
authors.affiliation: Department of Communicable Disease Control, Ministry of Public Health (MOPH), Bangkok, Thailand.
authors.forename: B
authors.initials: B
authors.lastname: Chunhaswasdikul
authors.forename: P
authors.initials: P
authors.lastname: Kamolratanakul
authors.forename: A
authors.initials: A
authors.lastname: Jittinandana
authors.forename: V
authors.initials: V
authors.lastname: Tangcharoensathien
authors.forename: S
authors.initials: S
authors.lastname: Kuptawintu
authors.forename: P
authors.initials: P
authors.lastname: Pantumabamrung
mesh_terms: D000553:Ambulatory Care; D000995:Antitubercular Agents / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D003365:Costs and Cost Analysis; D017048:Health Care Costs / Q000706:statistics & numerical data; D006801:Humans; D010349:Patient Compliance; D013785:Thailand; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy / Q000191:economics / Q000517:prevention & control*
chemical_list: D000995:Antitubercular Agents